Dosing Error Turns into Lucky Punch for AstraZeneca and Oxford

November 23, 2020

(Reuters) – A stroke of good fortune from a dosing error will pave the way for AstraZeneca and Oxford University to submit their COVID-19 vaccine for regulatory clearance. The British drugmaker said on Monday that the vaccine could be around 90% effective, when administered as a half dose followed by a full dose a month later, citing data from late-stage trials in Britain and Brazil.